| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
JAK3 INHIBITOR VI manufacturers
- JI6
-
- $163.00
-
2026-07-27
- CAS:856436-16-3
- Purity: 99.09%
- Supply Ability: 10g
|
| | JAK3 INHIBITOR VI Basic information |
| | JAK3 INHIBITOR VI Chemical Properties |
| storage temp. | +2C to +8C | | solubility | water: 1 mg/mL || DMSO: 5 mg/mL | | form | Yellow solid | | color | yellow | | Water Solubility | water: 1mg/mL
DMSO: 5mg/mL | | InChI | 1S/C18H13N3O.CH4O3S/c22-18-16(10-14-4-2-8-20-14)15-9-12(5-6-17(15)21-18)13-3-1-7-19-11-13;1-5(2,3)4/h1-11,20H,(H,21,22);1H3,(H,2,3,4)/b16-10-; | | InChIKey | ZUDPNBZMAJGYTE-HYMQDMCPSA-N | | SMILES | [S](=O)(=O)(O)C.[nH]1c(ccc1)\C=C2\c3c(ccc(c3)c4cnccc4)NC\2=O |
| WGK Germany | WGK 1 | | Storage Class | 11 - Combustible Solids |
| | JAK3 INHIBITOR VI Usage And Synthesis |
| Uses | JI6 is a potent, selective and orally active FLT3 inhibitor, with IC50s of ～40, 8, and 4 nM for FLT3-WT, FLT3-D835Y, and FLT3-D835H, respectively. JI6 also inhibits JAK3 and c-Kit, with IC50s of ～250 and ～500 nM, respectively. JI6 can be used for the research of acute myeloid leukemia[1]. | | General Description | A cell-permeable, potent, and reversible inhibitor of Janus kinase 3 (JAK3) (IC50 = 27 nM). Reported to bind to the enzyme active site and prevent IL-2-induced phosphorylation of JAK3 and STAT5. Also reported to inhibit IL-2-induced cell proliferation (IC50 = 760 nM for murine CTLL cells and 250 nM for human T-cells). Shown to alleviate oxazolone-induced ear edema in mice with an efficacy comparable to Dexamethasone (Cat. No. 265005) and displays ~16-fold greater selectivity over JAK2. | | Biochem/physiol Actions | Cell permeable: yes | | in vivo | JI6 (15 mg/kg; i.p. daily for 3 weeks) inhibits the proliferation of FLT3-D835Y-transformed HCD-57 in immunodeficient mice and prolongs the mice survival[1].
JI6 (25 mg/kg; p.o. daily for 3 weeks) suppresses myeloproliferative phenotypes in FLT3-ITD knock-in mice[1].
JI6 (100 mg/kg; a single i.p.) significantly inhibits phosphorylation of FLT3 and downstream signal transductionin mice expressing FLT3-D835Y[1].
| Animal Model: | NSG mice (10-12 weeks old, male) were implanted with FLT3-D835Y-transformed HCD-57 cells[1] | | Dosage: | 15 mg/kg | | Administration: | I.p. daily for 3 weeks | | Result: | Reduced the spleen size and prolonged the survival of these mice.
|
| | IC 50 | FLT3-D835H: 4 nM (IC50); FLT3-D835Y: 8 nM (IC50); FLT3-WT: 40 nM (IC50); JAK3: ~250 nM (IC50); c-Kit: ~500 nM (IC50) | | References | [1] Chen Y, et, al. Identification of an orally available compound with potent and broad FLT3 inhibition activity. Oncogene. 2016 Jun 9;35(23):2971-8. DOI:10.1038/onc.2015.362 |
| | JAK3 INHIBITOR VI Preparation Products And Raw materials |
|